89Zr-anti-γH2AX-TAT but not 18F-FDG allows early monitoring of response to chemotherapy in a mouse model of pancreatic ductal adenocarcinoma
<strong>Purpose:</strong> Late-stage, unresectable pancreatic ductal adenocarcinoma (PDAC) is largely resistant to chemotherapy and consequently has a very poor 5-year survival rate of < 5%. The ability to assess the efficacy of a treatment soon after its initiation would enable r...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
American Association for Cancer Research
2017
|